Daily Courier: Single Column

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

207.94 -4.46 (-2.10%)
Official Closing Price Updated: 7:00 PM EDT, Apr 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,632,951
Open 213.55
Bid (Size) 208.00 (100)
Ask (Size) 208.99 (200)
Prev. Close 212.40
Today's Range 207.75 - 214.10
52wk Range 164.39 - 244.81
Shares Outstanding N/A
Dividend Yield 3.33%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
3 Market-Beating Stocks with Competitive Advantages
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ... 
Via StockStory
News headline image
Gilead Sciences Solidifies Oncology Future with $5 Billion Acquisition of ADC Innovator Tubulis
In a bold move to dominate the rapidly evolving cancer treatment landscape, Gilead Sciences (Nasdaq: GILD) announced on April 7, 2026, its acquisition of the German biotech firm Tubulis for a total... 
Via MarketMinute
Topics Bonds

Performance

YTD
-9.3%
-9.3%
1 Month
-8.4%
-8.4%
3 Month
-7.2%
-7.2%
6 Month
-9.9%
-9.9%
1 Year
+15.6%
+15.6%

More News

Read More
News headline image
3 Dividend Aristocrats Whose Yields Can Help Combat Inflation ↗
Via MarketBeat
Topics Economy
News headline image
3 Companies Aggressively Raising Dividends While Others Play Defense ↗
Via MarketBeat
Topics Artificial Intelligence Economy
News headline image
This Investor's $5 Million ETF Buy Pushes 2028 Bond Fund to Nearly 4% of AUM ↗
Via The Motley Fool
Topics Bonds ETFs Regulatory Compliance
News headline image
This Fund's Ladder Strategy Expanded With a $4 Million Buy in One 2027 Bond ETF ↗
Via The Motley Fool
Topics Bonds ETFs
News headline image
Red Spruce Adds $3.35 Million to a 2029 Bond ETF With 4.5% Yield. Here's What Investors Should Know ↗
Via The Motley Fool
Topics Bonds ETFs Regulatory Compliance
News headline image
1 Healthcare Stock on Our Watchlist and 2 We Avoid
Via StockStory
News headline image
3 Absurdly Cheap Dividend Stocks to Buy in April 2026 ↗
Via The Motley Fool
Topics Economy
News headline image
This Pharma Dividend Has Been Raised Every Single Year for Over a Decade ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Should You Buy AbbVie Stock Before April 29? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
The "Liberation Day" Shockwave: US Finalizes 100% Tariffs on Branded Pharmaceutical Imports
Via MarketMinute
Topics Economy World Trade
News headline image
Regeneron Pharmaceuticals: The Scientific Juggernaut Navigating a High-Stakes Transformation
Via Finterra
Topics Economy Intellectual Property World Trade
News headline image
2 Healthcare Dividend Stocks to Buy as the Tech-Heavy Nasdaq Dips Below Correction Territory ↗
Via The Motley Fool
Topics Economy Retirement Stocks
News headline image
Merck’s Oncology Empire Expands: Keytruda Secures Pivotal European Commission Approval for Recurrent Ovarian Cancer
Via MarketMinute
Topics Intellectual Property
News headline image
AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie Shares Plummet, What You Need To Know
Via StockStory
Topics Government Stocks World Trade
News headline image
The New Blue-Chip: How Johnson & Johnson Refined Its Empire for a High-Growth Future
Via Finterra
Topics Artificial Intelligence Earnings Economy
News headline image
Gilead Sciences Acquires Ouro Medicines for $2.2 Billion to Lead 'Immune Reset' Revolution
Via MarketMinute
News headline image
Corcept Therapeutics Outperforms: How a Surprise FDA Approval Ignited a Late-March Rally
Via MarketMinute
Topics ETFs Intellectual Property Stocks
News headline image
Merck Just Made a Big Bet on a New Cancer Growth Engine ↗
Via MarketBeat
News headline image
This Top ETF Recently Added a Healthy Dose of These High-Yielding Dividend Stocks ↗
Via The Motley Fool
Topics ETFs Stocks
News headline image
1 Reason Eli Lilly Stock Is Still a Buy ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Eli Lilly Shares Slip Despite Positive Eczema Trial Results: Why the Market Reacted Coolly
Via MarketMinute
News headline image
Here's How Many Shares of AbbVie (ABBV) Stock You'd Need for $10,000 in Yearly Dividends ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
The 15-Minute Breakthrough: A Deep Dive into GH Research (GHRS) and the Future of Rapid-Acting Psychedelics
Via Finterra
Topics Cannabis Initial Public Offering Intellectual Property

Frequently Asked Questions

Is AbbVie publicly traded?
Yes, AbbVie is publicly traded.
What exchange does AbbVie trade on?
AbbVie trades on the New York Stock Exchange
What is the ticker symbol for AbbVie?
The ticker symbol for AbbVie is ABBV on the New York Stock Exchange
What is the current price of AbbVie?
The current price of AbbVie is 207.94
When was AbbVie last traded?
The last trade of AbbVie was at 04/10/26 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Daily Courier, Kelowna, BC. Powered by BLOX Content Management System from TownNews.com.